References The Use of Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis

20 June, 2018

References

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. The GOLD Scientific Committee. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001; 163: 1256-76.
2. Van Brabandt H, Cauberghs M, Verbeken E, Moerman P, Lauweryns JM, Van de Woestijne KP. Partitioning of pulmonary impedance in excised human and canine lungs. J Appl Physiol 1983; 55: 1733-42.
3. Yanai M, Sekizawa K, Ohrui T, Sasaki H, Takishima T. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol 1992; 72: 1016-23.
4. Mead J, Turner JM, Macklem PT, Little J. Significance of the relationship between lung recoil and maximum expiratory flow. J Appl Physiol 1967; 22: 95-108.
5. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709-21.
6. Wouters EF. Management of severe COPD. Lancet 2004; 364: 883-95.
7. Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-13.
8. Stockley RA, Bayley D, Hill SL, Hill AT, Crooks S, Campbell EJ. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax 2001; 56: 366-72.
9. WHO. World Health Report 2004. Available at http://www.who.int/whr/2004/en.
10. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
11. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ 2002; 51: 1-16.
12. Calverley PMA. Chronic Obstructive Pulmonary Disease: the key facts. London, UK: British Lung Foundation; 1998.
13. Guthrie R. Community-acquired lower respiratory tract infections: etiology and treatment. Chest 2001; 120: 2021-34.
14. Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-45.
15. Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003; 22: 931-6.
16. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117(Suppl 2): 380S-5S.
17. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-20.
18. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-71.
19. Hegele RG, Hayashi S, Hogg JC, Pare PD. Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory tract infections. Am J Respir Crit Care Med 1995; 151: 1659-64; discussion 1664-5.
20. Seemungal TA, Harper-Owen R, Bhowmik A, Jeffries DJ, Wedzicha JA. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000; 16: 677-83.
21. Anderson HR, Spix C, Medina S, Schouten JP, Castellsague J, Rossi G, Zmirou D, Touloumi G, Wojtyniak B, Ponka A, Bacharova L, Schwartz J, Katsouyanni K. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J 1997; 10: 1064-71.
22. Samet JM, Dominici F, Curriero FC, Coursac I, Zeger SL. Fine particulate air pollution and mortality in 20 U.S. cities, 1987-1994. N Engl J Med 2000; 343: 1742-9.
23. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542-8.
24. Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116: 40-6.
25. Allewelt M, Balk S, de Roux A, Mauch H, Niederman M, Lode H. A prediction model for bacterial etiology in acute exacerbations of COPD. (Submitted to Chest)
26. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941-7.
27. Lode H, Eller J, Linnhoff A, Ioanas M. Levofloxacin versus clarithormycin in COPD exacerbation: focus on exacerbation-free interval. Eur Respir J 2004; 24: 947-53.
28. Balter MS, Forge JL, Low DE, Mandell L, Grossman RF, the Chronic Bronchitis Working Group on behalf of the Canadian Thoracic Society and the Canadian Infectious Disease Society. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003; 10(Suppl B): 3B-32B.